The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies.
 
Sophie Cousin
No Relationships to Disclose
 
Laila Belcaid
No Relationships to Disclose
 
Kilian Trin
No Relationships to Disclose
 
Arnaud Bayle
Consulting or Advisory Role - Sanofi
 
Melissa Alame
No Relationships to Disclose
 
Etienne Rouleau
Honoraria - AstraZeneca (Inst); BMS (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Roche (Inst)
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS
 
Isabelle Soubeyran
Consulting or Advisory Role - Lilly O.; SERVIER
Speakers' Bureau - AstraZeneca (Inst); Roche (Inst)
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - MSD
 
Ludovic Lacroix
No Relationships to Disclose
 
Laura Blouin
No Relationships to Disclose
 
Damien Vasseur
No Relationships to Disclose
 
Simone Mathoulin-Pélissier
No Relationships to Disclose
 
Carine A. Bellera
Consulting or Advisory Role - BMS
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS